CEO: Mikko Mannerkoski

Advent Contact: Raj Parekh & Chris Baker

First-in-class small molecule modulators of PP2A

Rappta Therapeutics (“Rappta”) is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). Rappta has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumour growth, with the potential to create a new class of anti-cancer drugs.


Advent invested in the Series A in 2020.